Do analysts rate CPHI or UTZ?

Utz Brands has a consensus target price of $13.39, suggesting a potential downside of 6.16%. Given Utz Brands' stronger consensus rating and higher probable upside, analysts clearly believe Utz Brands is more favorable than China Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Utz Brands 1 Sell rating(s) 9 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is CPHI or UTZ more profitable?

Utz Brands has a net margin of -2.00% compared to China Pharma's net margin of -85.56%. Utz Brands' return on equity of 8.97% beat China Pharma's return on equity. Company Net Margins Return on Equity Return on Assets China Pharma -85.56% -63.93% -31.42% Utz Brands -2.00% 8.97% 4.32%

Does the media refer more to CPHI or UTZ?

In the previous week, China Pharma and China Pharma both had 1 articles in the media. Utz Brands' average media sentiment score of 0.42 beat China Pharma's score of 0.00 indicating that Utz Brands is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment China Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Utz Brands 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CPHI or RFAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 RF Acquisition Corp II 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, CPHI or RFAI?

RF Acquisition Corp II has lower revenue, but higher earnings than China Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio China Pharma $3.91M 7.22 -$3.08M -$0.43 N/A RF Acquisition Corp II N/A N/A N/A N/A N/A

Does the media prefer CPHI or RFAI?

In the previous week, China Pharma and China Pharma both had 1 articles in the media. RF Acquisition Corp II's average media sentiment score of 0.96 beat China Pharma's score of 0.00 indicating that RF Acquisition Corp II is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment China Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral RF Acquisition Corp II 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CPHI or AARD?

Aardvark Therapeutics has a consensus target price of $13.13, indicating a potential upside of 163.03%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aardvark Therapeutics is more favorable than China Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aardvark Therapeutics 2 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.36

Does the media refer more to CPHI or AARD?

In the previous week, Aardvark Therapeutics had 24 more articles in the media than China Pharma. MarketBeat recorded 25 mentions for Aardvark Therapeutics and 1 mentions for China Pharma. China Pharma's average media sentiment score of 0.00 equaled Aardvark Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment China Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aardvark Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 25 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CPHI or CPIX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer CPHI or CPIX?

In the previous week, Cumberland Pharmaceuticals had 1 more articles in the media than China Pharma. MarketBeat recorded 2 mentions for Cumberland Pharmaceuticals and 1 mentions for China Pharma. China Pharma's average media sentiment score of 0.00 equaled Cumberland Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment China Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cumberland Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CPHI or VTVT?

vTv Therapeutics has a consensus target price of $55.83, suggesting a potential upside of 82.64%. Given vTv Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe vTv Therapeutics is more favorable than China Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 vTv Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78

Does the media refer more to CPHI or VTVT?

In the previous week, vTv Therapeutics had 1 more articles in the media than China Pharma. MarketBeat recorded 2 mentions for vTv Therapeutics and 1 mentions for China Pharma. China Pharma's average media sentiment score of 0.00 equaled vTv Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment China Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral vTv Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

China Pharma (CPHI) Competitors

$0.66 +0.00 (+0.61%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$0.66 +0.00 (+0.30%)

As of 10/2/2026 08:00 PM Eastern

Compare

CPHI vs. UTZ, RFAI, AARD, CPIX, and VTVT

Should you buy China Pharma stock or one of its competitors? China Pharma's main competitors and comparable companies include Utz Brands (UTZ), RF Acquisition Corp II (RFAI), Aardvark Therapeutics (AARD), Cumberland Pharmaceuticals (CPIX), and vTv Therapeutics (VTVT). Companies are selected based on similarities in market, industry, and size.

How does China Pharma compare to Utz Brands?

China Pharma (NYSE:CPHI) and Utz Brands (NYSE:UTZ) are related companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

96.0% of Utz Brands shares are held by institutional investors. 6.4% of China Pharma shares are held by insiders. Comparatively, 12.7% of Utz Brands shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Utz Brands has higher revenue and earnings than China Pharma. Utz Brands is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.91M	7.22	-$3.08M	-$0.43	N/A
Utz Brands	$1.44B	1.43	$800K	-$0.33	N/A

China Pharma has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market. Comparatively, Utz Brands has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market.

Utz Brands has a net margin of -2.00% compared to China Pharma's net margin of -85.56%. Utz Brands' return on equity of 8.97% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
Utz Brands	-2.00%	8.97%	4.32%

In the previous week, China Pharma and China Pharma both had 1 articles in the media. Utz Brands' average media sentiment score of 0.42 beat China Pharma's score of 0.00 indicating that Utz Brands is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
China Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Utz Brands	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Utz Brands has a consensus target price of $13.39, suggesting a potential downside of 6.16%. Given Utz Brands' stronger consensus rating and higher probable upside, analysts clearly believe Utz Brands is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Utz Brands	1 Sell rating(s)	9 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Utz Brands beats China Pharma on 12 of the 15 factors compared between the two stocks.

How does China Pharma compare to RF Acquisition Corp II?

China Pharma (NYSE:CPHI) and RF Acquisition Corp II (NASDAQ:RFAI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

China Pharma has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, RF Acquisition Corp II has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market.

RF Acquisition Corp II has lower revenue, but higher earnings than China Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.91M	7.22	-$3.08M	-$0.43	N/A
RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A

RF Acquisition Corp II has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. RF Acquisition Corp II's return on equity of 0.00% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
RF Acquisition Corp II	N/A	N/A	N/A

In the previous week, China Pharma and China Pharma both had 1 articles in the media. RF Acquisition Corp II's average media sentiment score of 0.96 beat China Pharma's score of 0.00 indicating that RF Acquisition Corp II is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
China Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
RF Acquisition Corp II	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
RF Acquisition Corp II	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

RF Acquisition Corp II beats China Pharma on 6 of the 7 factors compared between the two stocks.

How does China Pharma compare to Aardvark Therapeutics?

China Pharma (NYSE:CPHI) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

China Pharma has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 3.8, meaning that its share price is 280% more volatile than the broader market.

China Pharma has higher revenue and earnings than Aardvark Therapeutics. Aardvark Therapeutics is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.91M	7.22	-$3.08M	-$0.43	N/A
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

In the previous week, Aardvark Therapeutics had 24 more articles in the media than China Pharma. MarketBeat recorded 25 mentions for Aardvark Therapeutics and 1 mentions for China Pharma. China Pharma's average media sentiment score of 0.00 equaled Aardvark Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
China Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aardvark Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	25 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aardvark Therapeutics has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
Aardvark Therapeutics	N/A	-71.54%	-64.94%

Aardvark Therapeutics has a consensus target price of $13.13, indicating a potential upside of 163.03%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aardvark Therapeutics is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.36

Summary

Aardvark Therapeutics beats China Pharma on 7 of the 13 factors compared between the two stocks.

How does China Pharma compare to Cumberland Pharmaceuticals?

China Pharma (NYSE:CPHI) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cumberland Pharmaceuticals has higher revenue and earnings than China Pharma. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.91M	7.22	-$3.08M	-$0.43	N/A
Cumberland Pharmaceuticals	$44.52M	2.49	-$2.84M	-$0.71	N/A

In the previous week, Cumberland Pharmaceuticals had 1 more articles in the media than China Pharma. MarketBeat recorded 2 mentions for Cumberland Pharmaceuticals and 1 mentions for China Pharma. China Pharma's average media sentiment score of 0.00 equaled Cumberland Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
China Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cumberland Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cumberland Pharmaceuticals has a net margin of -34.40% compared to China Pharma's net margin of -85.56%. Cumberland Pharmaceuticals' return on equity of -28.81% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
Cumberland Pharmaceuticals	-34.40%	-28.81%	-9.25%

China Pharma has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, Cumberland Pharmaceuticals has a beta of 0.06, suggesting that its share price is 94% less volatile than the broader market.

15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. 6.4% of China Pharma shares are held by company insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Cumberland Pharmaceuticals beats China Pharma on 9 of the 13 factors compared between the two stocks.

How does China Pharma compare to vTv Therapeutics?

China Pharma (NYSE:CPHI) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

17.5% of vTv Therapeutics shares are held by institutional investors. 6.4% of China Pharma shares are held by insiders. Comparatively, 6.0% of vTv Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

vTv Therapeutics has a consensus target price of $55.83, suggesting a potential upside of 82.64%. Given vTv Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe vTv Therapeutics is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

China Pharma has higher earnings, but lower revenue than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.91M	7.22	-$3.08M	-$0.43	N/A
vTv Therapeutics	$36.84M	3.27	-$26.97M	-$1.06	N/A

In the previous week, vTv Therapeutics had 1 more articles in the media than China Pharma. MarketBeat recorded 2 mentions for vTv Therapeutics and 1 mentions for China Pharma. China Pharma's average media sentiment score of 0.00 equaled vTv Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
China Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
vTv Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

vTv Therapeutics has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. vTv Therapeutics' return on equity of -6.27% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
vTv Therapeutics	N/A	-6.27%	-5.06%

China Pharma has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market.

Summary

vTv Therapeutics beats China Pharma on 10 of the 16 factors compared between the two stocks.

Get China Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPHI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CPHI vs. The Competition

Export

Metric	China Pharma	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$28.27M	$12.24B	$7.16B	$22.79B
Dividend Yield	N/A	2.64%	2.54%	3.73%
P/E Ratio	-1.53	799.70	275.66	27.75
Price / Sales	7.22	752.92	609.46	21.43
Price / Cash	N/A	86.66	78.87	38.23
Price / Book	0.94	10.46	10.93	4.64
Net Income	-$3.08M	$2.84B	$3.51B	$1.08B
7 Day Performance	-12.59%	-1.57%	-2.00%	-1.06%
1 Month Performance	-21.79%	-5.67%	-6.15%	-5.49%
1 Year Performance	-65.24%	-4.73%	7.44%	5.13%

China Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CPHI China Pharma	N/A	$0.66 +0.6%	N/A	-66.6%	$28.27M	$3.91M	N/A	221	News Coverage
UTZ Utz Brands	1.6401 of 5 stars	$14.25 +0.1%	$13.39 -6.0%	+17.0%	$2.05B	$1.44B	N/A	3,300
RFAI RF Acquisition Corp II	1.4843 of 5 stars	$31.65 -7.5%	N/A	+254.0%	$126.45M	N/A	N/A	2	News Coverage Short Interest Decrease
AARD Aardvark Therapeutics	3.79 of 5 stars	$5.55 -0.2%	$15.33 +176.3%	-67.5%	$125.83M	N/A	N/A	28	Trending News Analyst Forecast
CPIX Cumberland Pharmaceuticals	0.2537 of 5 stars	$8.01 +0.9%	N/A	+128.1%	$122.86M	$44.52M	N/A	93	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CPHI) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

China Pharma (CPHI) Competitors

CPHI vs. UTZ, RFAI, AARD, CPIX, and VTVT

How does China Pharma compare to Utz Brands?

Summary

How does China Pharma compare to RF Acquisition Corp II?

Summary

How does China Pharma compare to Aardvark Therapeutics?

Summary

How does China Pharma compare to Cumberland Pharmaceuticals?

Summary

How does China Pharma compare to vTv Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPHI vs. The Competition

China Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

China Pharma (CPHI) Competitors

CPHI vs. UTZ, RFAI, AARD, CPIX, and VTVT

How does China Pharma compare to Utz Brands?

Do institutionals and insiders hold more shares of CPHI or UTZ?

Which has better valuation and earnings, CPHI or UTZ?

Which has more risk & volatility, CPHI or UTZ?

Is CPHI or UTZ more profitable?

Does the media refer more to CPHI or UTZ?

Do analysts rate CPHI or UTZ?

Summary

How does China Pharma compare to RF Acquisition Corp II?

Which has more volatility and risk, CPHI or RFAI?

Which has stronger earnings and valuation, CPHI or RFAI?

Is CPHI or RFAI more profitable?

Does the media prefer CPHI or RFAI?

Do analysts rate CPHI or RFAI?

Summary

How does China Pharma compare to Aardvark Therapeutics?

Which has more risk and volatility, CPHI or AARD?

Which has better earnings and valuation, CPHI or AARD?

Does the media refer more to CPHI or AARD?

Is CPHI or AARD more profitable?

Do analysts recommend CPHI or AARD?

Summary

How does China Pharma compare to Cumberland Pharmaceuticals?

Do analysts rate CPHI or CPIX?

Which has stronger valuation and earnings, CPHI or CPIX?

Does the media prefer CPHI or CPIX?

Is CPHI or CPIX more profitable?

Which has more risk & volatility, CPHI or CPIX?

Do insiders & institutionals believe in CPHI or CPIX?

Summary

How does China Pharma compare to vTv Therapeutics?

Do insiders and institutionals believe in CPHI or VTVT?

Do analysts rate CPHI or VTVT?

Which has stronger valuation and earnings, CPHI or VTVT?

Does the media refer more to CPHI or VTVT?

Is CPHI or VTVT more profitable?

Which has more risk and volatility, CPHI or VTVT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPHI vs. The Competition

China Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools